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Mobile technology is all around and is a disruptive innovation.  
 
Anyone at EULAR 2018 may have noticed the electronic tags on their name badges. 
They may have been less aware that when they registered for the conference they 
signed an agreement for these GPS enabled devices to monitor which sessions they 
attended and when. The use of wearable technology to unobtrusively collect data 
about people’s movements, location, sleep patterns and activity levels is a rapidly 
advancing field of research and clinical interest. Combine data from body-worn or 
smartphone sensors with apps to log self-reported symptom experiences or life 
events, and we suddenly have insight into individuals’ daily lives like never before.  
 
A recent systematic review identified 17 apps available on Android or iOS, suitable for 
RA symptom monitoring, incorporating a range of validated and non-validated 
symptom tracking measures [1]. The smart-textile, smart-glasses, and wearable 
electronics sector advancing, with an estimated growth from $20 billion in 2015 to $70 
billion by 2025 [2]. With large-scale European funding calls for more digital technology 
research, and an increasing emphasis on private-public partnerships to meet the 
growing demand for innovation [3], we may all need to begin to think about how to 
integrate technology into our research plans and clinical practice.   
 
There are several obvious benefits for patients and care providers of incorporating 
technology into symptom measurement and management. Rheumatological 
conditions often involve a range of physical and psychological symptoms, challenging 
to capture in infrequent, time-limited outpatient appointments. Blood test results are 
often linked with patient-reported outcomes based on recollections from the previous 
±6 months, which may be subject to recall bias. Remote symptom measurement, 
through apps or wearables, allows cost-effective collection of a wide range of patient-
reported outcomes, allowing insight into symptoms experienced over time, in between 
clinic visits [4]. Mobile technology may also facilitate monitoring of symptoms 
prioritised by patients, but often neglected during appointments due to a lack of time 
or resources. Depression, for example, is known to be prevalent [5] and is associated 
with a range of adverse outcomes [6]. Traditional models of care can often struggle to 
find useful ways of measuring variability the wider symptom spectrum. With the aid of 
well-designed and integrated remote symptom measurement systems, we can move 
towards more personalized care, with patients selecting the outcomes which are most 
important to them, changing and adapting their symptom monitoring as their disease 
progresses and their treatments change.  
 
However, for technology to be meaningfully integrated into clinical care, the added 
value of new possibilities needs to be evaluated against the potential risks. Systematic 
review evidence has highlighted some of the barriers of engagement with technology 
for managing health, emphasizing several essential challenges faced by users when 
implementing digital innovation into daily routines [7]. Fluctuations in symptom severity 
were identified as a key barrier to long-term engagement; wearable technology needs 
to be robust in the face of symptom flare. Systems need to be flexible and compatible 
with existing routines, with timely notifications improving response rates, particularly 
in the early days of incorporating technology into daily habits [8]. Might accessing more 
information about one’s own health and symptoms, particularly in those with co-morbid 
depression or anxiety, increase health anxiety and promote unnecessary help-seeking 
behaviour? Arguably the most important criterion for successful development and 
implementation of wearable technologies into routine management is the user’s 
perceived utility of the system: are the risks worth the benefits? Can the technology 
provide something of intrinsic value to the individual, to improve self-awareness, health 
behaviours, and a sense of empowerment over an otherwise unpredictable disease 
course? 
 
Extensive research is needed to start answering these questions, and progress is 
already being made. The international research consortium, Remote Assessment of 
Disease and Relapse – Central Nervous System (RADAR-CNS; [9]) is already 
examining the utility of these technologies in major depressive disorder, multiple 
sclerosis and epilepsy. The REmote MOnitoring of Rheumatoid Arthritis (REMORA) 
project, led by the Professor of Digital Epidemiology at Manchester University, has 
already made great headway in developing and testing a symptom measurement app 
specific to Rheumatoid Arthritis (RA) [10]. There is little doubt that the age of wearable 
technology represents a paradigm shift in how long-term conditions are measured and 
managed. It is, however, a disruptive innovation, displacing current systems and 
practices, requiring careful and ongoing monitoring and evaluation.  
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